The association between urinary pentosidine levels and cognition in drug-naïve patients with Parkinson's disease.
Saved in:
| Title: | The association between urinary pentosidine levels and cognition in drug-naïve patients with Parkinson's disease. |
|---|---|
| Authors: | Omoto, Shusaku (AUTHOR), Saito, Mitsuru (AUTHOR), Murakami, Hidetomo (AUTHOR), Shiraishi, Tomotaka (AUTHOR), Kitagawa, Tomomichi (AUTHOR), Sato, Takeo (AUTHOR), Takatsu, Hiroki (AUTHOR), komatsu, Teppei (AUTHOR), Sakai, Kenichiro (AUTHOR), Umehara, Tadashi (AUTHOR), Mitsumura, Hidetaka (AUTHOR), Iguchi, Yasuyuki (AUTHOR) |
| Source: | Neurological Sciences. Nov2022, Vol. 43 Issue 11, p6323-6328. 6p. 3 Charts, 2 Graphs. |
| Subjects: | Parkinson's disease, Advanced glycation end-products, Montreal Cognitive Assessment, Movement disorders, Multiple regression analysis, Cognition |
| Abstract: | Advanced glycation end products (AGEs) are suggested to play a potential role in the progression of Parkinson's disease (PD). The association between urinary levels of pentosidine, one of the best-characterized AGEs, and clinical conditions such as motor severity and cognition were investigated in patients with PD. Data on the clinical characteristics and urinary levels of pentosidine for 44 drug-naïve patients aged 60 years or older with PD were collected. The association between urinary pentosidine levels and severity of motor symptoms and cognition was analyzed using the Montreal Cognitive Assessment Scale (MoCA). Urinary pentosidine values increased with age (R2 = 0.286, p < 0.001) and were negatively correlated with the MoCA score (R2 = 0.255, p = 0.001). Urinary pentosidine levels were significantly correlated with age (r = 0.535, p < 0.001), Hoehn-Yahr stage (r = 0.340, p < 0.05), and total MoCA score (r = − 0.505, p < 0.001). Multiple linear regression analysis showed that older age (β = 0.543; 95% confidence interval [CI] 0.300, 1.307; p = 0.003) was significantly associated with severity of motor symptoms, and that older age (β = − 0.456; 95% CI − 0.287, − 0.054; p = 0.005) and urinary pentosidine levels (β = − 0.311; 95% CI − 0.428, − 0.004; p = 0.046) were significantly associated with a lower MoCA score. Urinary pentosidine levels were significantly associated with lower cognition in drug-naïve PD patients. These findings have important clinical implications and suggest that pentosidine may be a potential marker for cognitive impairment in early PD. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Advanced glycation end products (AGEs) are suggested to play a potential role in the progression of Parkinson's disease (PD). The association between urinary levels of pentosidine, one of the best-characterized AGEs, and clinical conditions such as motor severity and cognition were investigated in patients with PD. Data on the clinical characteristics and urinary levels of pentosidine for 44 drug-naïve patients aged 60 years or older with PD were collected. The association between urinary pentosidine levels and severity of motor symptoms and cognition was analyzed using the Montreal Cognitive Assessment Scale (MoCA). Urinary pentosidine values increased with age (R2 = 0.286, p < 0.001) and were negatively correlated with the MoCA score (R2 = 0.255, p = 0.001). Urinary pentosidine levels were significantly correlated with age (r = 0.535, p < 0.001), Hoehn-Yahr stage (r = 0.340, p < 0.05), and total MoCA score (r = − 0.505, p < 0.001). Multiple linear regression analysis showed that older age (β = 0.543; 95% confidence interval [CI] 0.300, 1.307; p = 0.003) was significantly associated with severity of motor symptoms, and that older age (β = − 0.456; 95% CI − 0.287, − 0.054; p = 0.005) and urinary pentosidine levels (β = − 0.311; 95% CI − 0.428, − 0.004; p = 0.046) were significantly associated with a lower MoCA score. Urinary pentosidine levels were significantly associated with lower cognition in drug-naïve PD patients. These findings have important clinical implications and suggest that pentosidine may be a potential marker for cognitive impairment in early PD. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-022-06332-0 |
